Rick Jory, Board Chair
President & CEO
Sandhill Scientific, Inc.

Rick Jory is President & CEO of Sandhill Scientific, Inc., a medical device manufacturer that specializes in diagnostic devices mainly used by gastroenterologists and endoscopic surgeons. He holds a degree in Industrial Engineering and an MBA in Finance. Past experience includes work with both Cobe Laboratories and Valleylab. He is past Board Chair of the South Metro Denver Chamber of Commerce and former President of the CMDA.

Joe Bagan, CEO/President
Sharklet Technologies

Joe Bagan brings more than 20 years of strategic leadership, executive management and a proven track record in senior-level positions to Sharklet Technologies. As CEO, Mr. Bagan leads Sharklet Technologies' business development activities and the commercialization strategy that will deliver Sharklet, the company's core surface technology, to market.

Prior to joining Sharklet Technologies, Mr. Bagan served in a variety of executive roles where the hallmark of his success has been his keen ability to organize, drive and implement complex projects with great success. Mr. Bagan most recently served as senior vice president of Adelphia Communications' southeast region where he led all business functions and held full P&L responsibility for a seven-state territory. In this leadership position, he launched multiple advanced services and guided the company's regional network upgrade efforts.

Prior to joining Adelphia in 2003, he served as chief financial officer for Ricochet Wireless Networks, a Denver-based technology start-up company. During his tenure at the company, he led the effort to finance the business plan and successfully completed a B round of financing. Mr. Bagan also has expertise in leading multi-billion dollar initiatives as he served in various executive capacities at AT&T Broadband from 2000 to 2002 which included roles such as merger leader, chief information officer and senior vice president of billing operations. Mr. Bagan was recruited to AT&T from Arthur Andersen where he as the partner in charge of the Southwestern United States' consulting practice in several key industries.

Larry O. Blankenship
ValveXchange

Larry Blankenship is CEO and Chairman of ValveXchange, Inc., an Aurora, Colorado based company developing an innovative new heart valve technology.

Larry is a serial entrepreneur, engineer and inventor with more than 30 years experience encompassing business development, strategic planning, start-ups, turnarounds, product development, project management, and regulatory affairs. His product-specific experience encompasses heart valves, cardiac catheters, electrophysiology, surgical instruments, patient monitoring, drug delivery, urology products, angioscopy, ureteroscopy, laparoscopy, and arthroscopy. He has been involved in the Colorado medical device scene since 1985, with numerous business development and product introduction activities including successful start-ups and acquisitions.

Mr. Blankenship previously held executive positions at the IVAC division of Eli Lilly, Vitalmetrics, Inc. (acquired by Tyco), the Valleylab division of Pfizer (now part of Covidien) and CardioOptics. Larry was also CEO and co-founder of The Larren Corporation, a Colorado medical device development company later acquired by the Battelle Memorial Institute, where Larry served as Vice President of Medical Programs.

Over the course of his career, Larry has been responsible for overseeing the definition, design, development, manufacturing, regulatory approval and market introduction of dozens of medical devices. He holds 10 US patents and serves on several boards of directors and advisory boards.

James D. Chrisman, Senior Vice President
Forest City

Jim Chrisman is the Senior Vice President for Forest City, the development company who is working in partnership with the Fitzsimons Redevelopment Authority to create a nationally and internationally renown life science park. Mr. Chrisman is the principal in charge of the Fitzsimons project on behalf of Forest City.

In addition, Mr. Chrisman is responsible for office, retail, industrial and multi-family development at the former Stapleton International Airport which Forest City is transforming into a new community of 12,000 homes, 35,000 jobs and more than 1,100 acres of parks and open space.

Prior to joining Forest City Stapleton, Inc., Mr. Chrisman worked as a Vice President for the Stapleton Development Corporation, where he managed the conveyance of the property from the City and County of Denver to the private sector and the Stapleton Redevelopment Foundation, where he managed the preparation of the award winning Stapleton Development Plan.

Prior to that, Mr. Chrisman worked for Disney Development Company, Watt Industries, and Cadillac Fairview Corporation in southern California. He is currently on the Board of Directors of the local chapter of the National Association of Office and Industrial Properties. He holds a Bachelor of Science in Applied Mathematics and Administration and Management Science from Carnegie-Mellon University and a M.B.A. from the University of California, Berkeley.

Chris Clement, Senior Director Contracts & Business Operations
Taligen Therapeutics, Inc.

Dr. Chris Clement is a dynamic internal process and business operation executive with more than 20 years of experience with the business and scientific community. Dr. Clement received is Maitrise from Rennes (France) and his PhD from Exeter University (UK). He went on to Harvard for a Post Doctorate in cardiovascular diseases. Since, Dr. Clement has gradually moved into Strategy and Operations using his scientific background for its inquisitive, logical and multi-tasking values. While in Boston, Dr. Clement served at several Harvard affiliated institutions (Center for Blood Research, the Dana Farber Cancer Center) and then moved to Millennium Pharmaceuticals, Inc. where he implemented company-wide projects and refocused the outsourcing strategy. Since moving to Boulder, Colorado Dr. Clement has been consulting and working with several companies providing focused organizational leadership, contract management and support to identify next sets of deliverables. Currently, Dr. Clement is the Senior Director, Contracts and Business Operations at Taligen Therapeutics.

Derek Cole, Vice President, Investor Relations
ARCA Biopharma

Derek Cole is vice president, investor relations and corporate communications for ARCA biopharma Inc., Bloomfield, CO.

Cole has been involved in the capital markets and strategic planning for over 17 years with 12 years of dedicated investor relations experience focused on supporting the development of small- and mid-cap companies. He has managed or contributed to a broad spectrum of financing transactions, raising approximately $800 million, as well as supporting four M&A transactions. Cole was recently with Allos Therapeutics, Inc. as their vice president, investor Relations. Prior to Allos, Cole headed the investor relations and corporate communications function at Myogen, Inc., from its days as a private company, through its Initial Public Offering and continuing until its recent $2.5 billion acquisition. He is an active member of the National Investor Relations Institute (NIRI) currently serving as President of the Rocky Mountain Chapter and as a member of the BioPharma Roundtable steering committee. Cole is also on the Board of Directors of the Colorado BioScience Association (CBSA).

Lisa Drake, Director, Government Affairs
Monsanto Company

Lisa Drake is the Director of Government Affairs for Monsanto, responsible for management of the state and local government affairs team, ensuring freedom to operate in state legislatures and at the local level in the 50 United States and Puerto Rico.

Prior to work in Government Affairs, Lisa was Director of Public Affairs for Monsanto's Agricultural Sector, managing global media relations and issues management for the company's leading herbicide, Roundup herbicide and several of its biotechnology seeds businesses. Lisa works in Englewood and was born in Boulder. She earned her BA degree in Technical Journalism from Colorado State University. She has worked for Monsanto for 20 years. Prior to that she worked for two trade associations in California and worked as a reporter for several daily and weekly newspapers in Colorado, Mississippi and Alabama.

Dr. Richard Duke, President
ApopLogic Pharmaceuticals, LLC

John Dunning, President and CEO
Clarimedix Inc.

John Dunning, is President and CEO of Clarimedix Inc., a therapeutic medical device company based in Boulder, CO. Mr. Dunning brings a diverse background with significant start-up experience and an understanding of the financing and management processes associated with equity-backed companies. Prior to his time with Clarimedix, John was an investor at Wasatch Venture Fund, where he focused on a mixture of life science and technology investing while successfully raising a $12 million side car fund for Wasatch. Prior to joining Wasatch, John contributed at several start-ups in the San Francisco Bay Area where he had roles in operations and business development. Mr. Dunning holds a B.A from the University of Oregon and an M.B.A. from Thunderbird, the American Graduate School of International Management.

John Eckstein, Attorney/Shareholder
Fairfield & Woods

John Eckstein focuses upon the representation of emerging and middle market technology-oriented companies and venture capital funds, investors, investment bankers, financial advisors and financial institutions as an attorney for Fairfield & Woods. He also regularly provides legal counsel regarding finance and corporate governance to a number of large corporations. He is actively involved in legal and public policy aspects of biomedical, telecommunications and information technologies.

He has been chairman of the Colorado Advanced Technology Institute, a member of advisory committees to the Colorado Securities Commissioner and on technology issues to Governors Owens and Romer, Chair of the Colorado Biotechnology-Medical Technology Roundtable, President of the Colorado Chapter of the Federal Bar Association and President of the Denver Chapter of the Licensing Executives Society. He often speaks on securities, financing and technology topics to legal and business groups. John Eckstein has also been listed in Colorado Superlawyers, Corporate Counsel Black Book, Who’s Who in American Law and Who’s Who in High Tech in Denver/Boulder.

Jill Sikora Farnham, Executive Director
Fitzsimons Redevelopment Authority

Ms. Farnham is currently the Executive Director for the Fitzsimons Redevelopment Authority, after serving for six years as the Authority’s Director of Finance and Business Operations. The FRA is a partnership of the City of Aurora and the University of Colorado and is responsible for overseeing the creation of the Fitzsimons Life Science District as a world class environment for life science companies. The FRA directs the commercial developments in the District, including the Colorado Science +Technology Park at Fitzsimons, along with its partner, Forest City Enterprises.

Ms. Farnham oversees a variety of development issues for the Authority, including land acquisition, land sales, lease negotiations and management of developer contracts. She also oversees the Authority’s business incubation programs as well as its financial and administrative operations.

Prior to joining the FRA, Ms. Farnham was involved in private commercial real estate management and development in Colorado, working with various retail and commercial projects including the Inverness Business Park and the Denver Design Center. She also practiced as a Certified Public Accountant with Deloitte & Touche. Ms. Farnham is active with CREW-Denver, the Colorado BioScience Association and the Aurora Economic Development Council.

Jay Gershen, Executive Vice Chancellor
University of Colorado Denver

Dr. Jay Gershen is Executive Vice Chancellor at the University of Colorado Denver. He has played a leadership role to create the University of Colorado’s 21st century Health Sciences Center at the former Fitzsimons Medical Army Garrison in Aurora. Furthermore he has been the point person for interactions and collaborations with the business community and has worked to reformulate the vision and strategic directions for the Bioscience Research Park at Fitzsimons. Dr. Gershen has also made significant contributions to national policy making and advocacy regarding research, education and heath issues.

Dick Hinson, Senior Vice President
Aurora Economic Development Council

Dick Hinson is Senior Vice President of the Aurora Economic Development Council (EDC), Inc. Aurora EDC is a public/private partnership dedicated to enhancing the economic strength of the city of Aurora by recruiting new primary employers, retaining existing primary employers and assisting current primary employers to expand in the city. The public sector partners are the city of Aurora, Arapahoe County and Adams County. The private sector partners are the top one hundred companies doing business in Aurora.

As Senior Vice President, Hinson is responsible for Aurora EDC’s financial operations. He is also involved in the organization’s strategic planning, marketing strategies, and the development of strategic relationships, specifically in the areas of bioscience, aerospace, and regional economic development.

Dick has been employed in the field of economic development for over thirty years. He joined Aurora EDC in 1992. Hinson was previously the Economic Development Manager for the City of Thornton, the Executive Director of the Englewood Urban Renewal Authority, and an economist with the Knoxville/Knox County, Tennessee Metropolitan Planning Commission.

He earned a Bachelor of Science in Business Administration and a Master of Arts in Economics from the University of Tennessee at Knoxville.

Hinson is a member of the Economic Development Council of Colorado. He is a graduate of the International Economic Development Council’s Economic Development Institute and has received IEDC’s designation of Certified Economic Developer (CED).

Dick serves as Vice Chair of the Board of Directors of the Colorado Space Business Roundtable and represents Aurora EDC on the Colorado Space Coalition. He is Past President of Colorado Lending Source, a certified development corporation and past Vice Chair of the Colorado Competitive Council. He was 2007 Chair of the Metro Denver Economic Development Corporation Economic Development Professionals and served on the Executive Committee of the Metro Denver Economic Development Corporation.

Maggie Holben, Principal
Absolutely Public Relations

Maggie Holben, owner of Denver's Absolutely Public Relations, is accredited by the Public Relations Society of America and is a member of the PRSA Counselors Academy. In addition, she is certified as an industry analyst relations practitioner. Holben's consultancy offers several online newsrooms to assist clients, including PublicRelationsNewsroom.com, Expert411.com and DenverPRNewsroom.com. Frequently interviewed as a Public Relations Expert by the media, Holben holds a B.A. in Journalism from the University of Oklahoma and has taught both advertising and PR courses at the university level.

Jim Kasic, Director of Clinical Research
Otologics

Mr. Kasic has 20 years of experience in the Class II and III medical device industry. He has managed various functions at a senior or executive level including Manufacturing, Research and Development, Quality, Engineering, Sales, Marketing and Business Development. His range of experience is with large, multi-national organizations as well as a successful start-up with a domestic and international scope. Among his accomplishments can be listed the development of several unique implantable medical devices in vascular and the otolaryngology fields. Several of these devices were carried from the conceptual stages to commercial introduction. Mr. Kasic has been responsible for creating and successfully executing strategies in product and market development having built engineering, research, and sales and marketing organizations. THese activities have resulted in over 30 US and International patents, dozens of scientific publications, US and foreign device approvals and the successful international launch of several products. Mr. Kasic holds a BS in Physics, a MS in Chemical/Biological Engineering and an MBA.

Carin Kutcipal, Partner
Hogan & Hartson

Carin Kutcipal advises public and private companies and investors in corporate, securities, merger and acquisition, and financing matters. Carin represents public companies, public and private acquirers and targets in acquisition transactions, early stage and venture-backed companies, and private equity and venture capital firms.

Carin’s practice involves a full range of corporate and commercial transactions, mergers and acquisitions, public offerings, venture capital financings, corporate governance, and securities law compliance matters. Carin counsels clients in a range of industries, including aviation, information technology, data storage, biotechnology, medical devices, telecommunications, and retail.

Chris Lepore, Director, State Government Affairs
Johnson & Johnson

Chris joined Johnson & Johnson in 2004 bringing with him 12 years of legislative and regulatory experience. Before joining Johnson & Johnson he was Manager of State Government Affairs for Schering-Plough Corporation, where he was responsible for the corporation's lobbying efforts in Arizona, Colorado, New Mexico, Utah, and Wyoming. In addition to Chris’ industry experience, he has been a contract lobbyist in Colorado and Wyoming, representing the business interests of Hoffman LaRoche, the Colorado Association of Commerce and Industry, the Business Council for Health Care, and served on the PAC of the National Federation of Independent Business. Chris has served as the Vice Chair of PhRMA in Utah and Wyoming and is Chair of PhRMA in Colorado. He represents J&J interests in Colorado, Montana, Nevada and Wyoming.

James Linfield, Partner
Cooley Godward Kronish

James Linfield is Managing Partner of the Colorado office of Cooley Godward Kronish. Jim’s practice focuses on representation of public and private technology companies and venture capital funds with an emphasis on corporate finance, mergers and acquisitions and strategic alliances. His clients include many of Colorado’s leading public and private life science companies. He has a number one ranking in Corporate/M&A according to the Chambers USA Guide and is listed in The Best Lawyers in America. In 1980, Mr. Linfield received his J.D. Magna Cum Laude from Harvard Law School where he was also an editor of the Harvard Law Review. He received his A.B. Magna Cum Laude from Harvard College in 1977.

Mark Lupa, Partner
Tango Investments

Dan J. Mitchell, Partner
Sequel Venture Partners

In 1997 Dan co-founded Sequel Venture Partners, a leading venture fund in Colorado. Sequel currently manages over $410 million in three funds. Dan’s investment focus is primarily on start-up healthcare and biotechnology companies in the Front Range of Colorado.

In 1985 Dan co-founded Capital Health Venture Partners, a health care focused venture capital firm based in Chicago and Denver. As a Partner with Capital Health, Dan focused primarily on early-stage investments across healthcare.

Dan currently serves as a director of Replidyne (NASDAQ:RDYN), GlobeImmune, IntelliDX, Kalypto Medical, and Sierra Neuropharmaceuticals.

He received a BS-finance in 1979 from the University of Illinois and an MBA in 1981 from the Graduate School of Business at UC-Berkeley.

Sean Moriarty, President
QLT USA, Inc.

Sean Moriarty is the President of QLT USA, Inc., the Fort Collins based subsidiary of QLT Inc. QLT is a global biopharmaceutical company specializing in developing treatments for cancer, eye diseases and dermatological and urological conditions. QLT USA was created when QLT acquired Atrix Laboratories, Inc. in late 2004. Prior to joining QLT, Sean was the Director of Business Development at Geneva Pharmaceuticals, Inc. in Broomfield, Colorado and an attorney at Isaacson, Rosenbaum, Woods & Levy in Denver. He received his BS Engineering and Applied Sciences degree in 1985 from California Institute of Technology in Pasadena, California and JD from the University of Colorado, Boulder in 1996.

Terry Opgenorth, Chief Operating Officer
MicroRx and NeoTREX, CSU Ventures, Inc.

Terry Opgenorth serves as COO for MicroRx and NeoTREX, the enterprise arms of Colorado State University’s Infectious Disease and Cancer Superclusters. He joined CSU Ventures, Inc. in 2007 after 20 years with Abbott Laboratories, North Chicago, IL. His last position at Abbott was as Divisional Vice President of Metabolic Disease Research, Antiviral Research and Target-Lead Discovery Research for Abbott’s Global Pharmaceutical Research and Development division. He championed a number of biotech collaborations, and teams he led advanced 10 novel drug candidates to clinical development status with atrasentan reaching Phase III and NDA filing; others are in various stages of development. He was also a Research Fellow in Abbott’s Volwiler Society.

He serves on Scientific Advisory Boards for Keystone Symposia and Euroscreen, SA, and is a Section Editor for Current Opinions in Investigational Drugs. He is an author on 130 peer-reviewed publications, 9 book chapters or reviews, and an inventor on 3 patent applications. Dr. Opgenorth holds a BA in Biology from Calvin College, and MS and PhD degrees in Physiology from University of Illinois-Urbana.

Steve Orndorff, Ph.D., President/CEO
Accera, Inc.

Steve Orndorff is a serial entrepreneur with more than 25 years experience in the biotechnology industry. Mr. Orndorff is the current President and CEO of Accera. He is also the former President and CEO of Univera Pharmaceuticals, Inc., a drug discovery company focused on diseases of inflammation and the immune response.

During his career he has had responsibility in a broad array of disciplines such as basic research, manufacturing, product development and business development at various biotechnology companies including Genex Corporation, NutraSweet, Inc. and ZeaGen, Inc. Dr. Orndorff is a past President of the Society for Industrial Microbiology and a founding board member of the Colorado BioScience Association. He received a BS degree in Biology from Virginia Tech and a Ph.D. in microbiology from University of Maryland.

John M. Poate, VP for Research & TT
Colorado School of Mines

John Poate is Vice President of Research and Technology Transfer, Colorado School of Mines; a position he assumed in January 2006. Prior to assuming his present position, he was Chief Technology Officer and Vice President of Axcelis Technologies; a position he assumed in June, 2000. He was also Dean, from 1997 – 2000, of the College of Science and Liberal Arts of the New Jersey Institute of Technology (NJIT). The bulk of Poate’s research career was spent at Bell Labs as Department Head of the Silicon Processing Research Department.

Poate obtained his BSc and MSc in Physics from Melbourne University and PhD in Nuclear Physics from The Australian National University. He has over 300 publications in archival journals and 12 patents. He is past President and Councillor of the Materials Research Society and past Chair of the Division of Materials Physics of the American Physical Society. Poate is a Fellow of the American Physical Society and Editor of Applied Physics Reviews. He is Past Chair of the Physical and Engineering Sciences Panel for NATO. In 2002 he received the John Bardeen Award of The Metallurgical Society. In March 2008 he was inducted as a foundation Fellow of the MRS.

Linda Pryor, Director of Government Relations
Pfizer Pharmaceutical Company

Linda Pryor is Director of Government Relations and Public Affairs for Pfizer. In addition to serving on the Board of the Colorado Biosciences Association, Linda serves on the Colorado Civil Justice League Board, the University of Colorado School of Medicine Dean’s Advisory Council, the University of Colorado School of Nursing Board and is a member of numerous other civic and agricultural organizations. Prior to joining Pfizer, she served as Director of Public Affairs and chief lobbyist for the University of Colorado system. Linda Pryor holds a Bachelor of Science degree in Business Administration and a Master’s degree in Public Administration.

Rae Reynolds, President
Kaleidoscope Group, Inc.

Rae Reynolds has 30 years of experience in marketing and business development in the biotech industry. Ms. Reynolds served as the Vice President of Marketing for Cochlear Corporation to launch, and promote a market leading product line, build the market, and complete a successful IPO. She has helped commercialize and promote a range of additional biotech products and services through skills in competitive analysis and positioning, product launch, and corporate partnering and acquisition. Her experience includes assisting entrepreneurial companies secure early-stage capital through the NIH’s Small Business Innovation Research (SBIR) grant process.

Ms. Reynolds earned a BA in Economics from the University of Denver. She attended Johns Hopkns School of Advanced International Studies, and received a Masters in Planning from University of Colorado. Personal interests include skiing, hiking, tennis, and bicycling. She volunteers with a microcredit program to promote economic development in Guatemala.

Tom Roach, Partner
Ernst & Young

Tom Roach is an Audit Partner with Ernst & Young LLP and has spent more than 24 years with the firm focusing on health sciences industry. He is responsible for the firm’s Colorado health sciences practice serving various public and private companies. Tom has extensive financial accounting and auditing experience in acquisition, due diligence, stock and debt offerings plus analysis of acquisitions and business combinations. He is also a national Ernst & Young Focus Team Coach and audit methodology instructor. Tom Roach is a CPA holding licenses in Colorado, Missouri, Ohio, Oregon, New Mexico and Washington.

Norwood Robb, Board President
Denver School of Science and Technology

Norwood Robb is the Board President of the Denver School of Science and Technology. Mr. Robb also served on the University of Colorado Board of Regents representing the 6th Congressional District for 18 years and is now Regent Emeritus. He has had two different business careers, first working for large corporations and then as the owner of his own companies. His education includes a Master of Business Administration in Management and a Bachelor of Science in Mechanical Engineering from the University of Denver. He also completed course work for a Master of Science in Operations Research and Graduate Certificate Program in Alternate Dispute Resolution.

William Roberts, Attorney
Hogan & Hartson, LLP

Bill Roberts is the managing partner of the Hogan & Hartson’s Boulder, Colorado office and practices in the areas of corporate and securities and venture capital law, focusing on emerging company representation. Bill's practice involves a full range of corporate and commercial transactions including mergers and acquisitions, venture capital transactions, private placements and public offerings, project finance, commercial and employment contracts, loans, strategic alliances and general corporate matters. His practice in recent years has focused on advising emerging companies in strategic areas, including formation documents, acquisitions, financing transactions, and private and public offerings of debt and equity securities. Bill also has extensive experience with corporate restructuring, reorganization and recapitalization as well as energy transactions.

Frank Ronchetti, Chief Financial Officer
Biodesix, Inc.

Frank Ronchetti is the Chief Financial Officer of Biodesix, a molecular diagnostics company developing tests for early detection, diagnosis, therapeutic guidance, and monitoring in cancer and degenerative diseases. Previously, he was Chief Financial Officer of NetRegulus, a regulatory compliance software company that was sold to Parametric Technology Corporation (Nasdaq: PMTC). Prior to that, he was a Director in the London office of General Electric's venture capital arm, GE Equity. He also founded a corporate finance boutique in the Czech Republic, ran Central European acquisition finance for Erste Bank, the region's leading financial institution, and negotiated corporate sponsorship agreements on behalf of the International Olympic Committee. Frank has a BA in Economics from Stanford University, and an MBA from the Anderson School at UCLA.

Harry Ross, Managing Partner
Aweida Capital Management

Harry Ross received his Doctor of Medicine degree from Oregon Health Science University in 1991. He then went on to receive post graduate training in Surgery and Emergency Medicine at Hennepin County Medical Center with subsequent National Board Certification in Emergency Medicine. Dr. Ross retired from clinical practice in 1998 to join Aweida Capital where he is a Managing Partner specializing in the Life Sciences.

Aweida Capital Management is a 15 year old Evergreen Fund responsible for the management of its own private assets. The fund participates from early seed to late mezzanine rounds with preferred lifetime investments within a company of $5-10 million. Areas of interest are Life Sciences, Software, Data Storage, and Alternative Energy. The fund currently has $100 million under management.

Michael Salem, M.D., FACS, CEO/President
National Jewish Medical and Research Center

Michael Salem, M.D., FACS, began his tenure as President and CEO of National Jewish Medical and Research Center in January 2006, bringing to the position a combination of academic and business experience in the healthcare field.

A native of Washington, D.C., Dr. Salem received his undergraduate degree at Washington University in St. Louis, and then returned to his hometown for his medical degree from George Washington University School of Medicine and Health Sciences. He completed his surgical residency training at Boston University Hospital and George Washington University Hospital. He also completed research and clinical fellowships in Critical Care Medicine at Massachusetts General Hospital in Boston and Johns Hopkins Hospital in Baltimore.

After the completion of his medical training, Dr. Salem practiced and taught general surgery and critical care at George Washington University Hospital, where he later served as Vice Chairman of the Department of Surgery. Later in his career, Dr. Salem served as the Executive Vice President of a healthcare company that develops and commercializes biotechnology and medical technology products from academic medical centers. He led the research and development operations of that company, building research facilities and programs and navigating the regulatory process to bring discoveries to the marketplace.

In his first year at National Jewish, Dr. Salem led a comprehensive, broad-based strategic planning process that included faculty, staff, Board members, the Council of National Trustees and healthcare leaders from around the world. The ten year vision and plan, approved by the Board of Directors in January 2007, is a compelling set of ideas and solutions that will result in the integration of research and clinical efforts at the point of the patient. The plan will allow National Jewish to continue to innovate and lead as a medical center, remain preeminent in its areas of focus, maintain its collegial culture and grow substantially over time.

Rahmat Shoureshi, Dean and Professor
University of Denver

Dr. Rahmat Shoureshi's areas of research include Bioengineering, Biomimetics, Autonomic Structures, Smart Buildings, Bio-mechatronics, Automation and Robotics, Intelligent Electric Power System, Advanced Sensor and Actuator Systems and Intelligent Monitoring and Diagnostics. He is the former President of the Colorado Alliance for Bioengineering and is Chairman of the Board for Colorado Nanotechnology Alliance and serves on several other boards.

Jim Skrine, Executive Director, Quality
Amgen, Inc. Colorado

Executive Director of Quality, Jim Skrine, oversees the Quality Assurance, Product Quality, Quality Control, Validation and Compliance Groups for Amgen Colorado. Immediately prior to his current post, Skrine served as Director of Manufacturing and Plant Manager for Amgen Commercial Bulk Manufacturing in Thousand Oaks, California. There he had oversight for the manufacturing of the drug substance for six commercially marketed products; Epogen®, Aranesp®, Neupogen®, Neulasta®, Infergen®, and Stemgen®.

Mr. Skrine has been at Amgen for nearly seventeen years and began his career as a Protein Chemist in the Research and Development organization.

Mr. Skrine earned a Bachelor’s degree in Mathematics from Saint Vincent College in Latrobe, Pennsylvania and a Bachelor’s degree in Biology from the University of California, Santa Barbara. He is currently a member of the Parental Drug Association (PDA) and serves on the Board of Directors for HospiceCare of Boulder and Broomfield Counties.

Kevin Smith, Managing Director
Act Three Consulting, LLC

Kevin is the Managing Director of Act Three Consulting, LLC. Act Three was formed in July 2007 to provide consulting services to management teams and their advisors during times of dramatic change. Prior to founding Act Three, Kevin spent nine years as President of Gambro, Inc., the US holding company for the publicly-traded, Swedish-based Gambro Group, until its acquisition by private equity investors in 2006. The US operations of Gambro included the manufacture and distribution of cardiovascular (CV), blood separation and renal dialysis products and the operation of US and international kidney dialysis centers. As a member of the Gambro AB Executive Committee, Kevin was actively involved in strategy matters and took lead roles in many projects, including the sale of the CV business to an Italian group, the sale of the US dialysis business to a US public company for over $3 billion and the establishment of selected corporate functions in the standalone subsidiaries after the private equity transaction. Before joining Gambro, Kevin was an audit partner in the Denver and New York offices of Ernst & Young.

Rulon Stacey, Ph.D., President/CEO
Poudre Valley Health System

Rulon Stacey, Ph.D. first came to Colorado in 1989 when he was appointed as the Chief Executive Officer of St. Vincent General Hospital in Leadville. He served in that post for 5 years. During that time he was recognized by the leading healthcare administration journal as one of the 12 “up and coming” healthcare administrators in the country for his innovative plans to address the issues specific to rural healthcare.

After a brief stay in Chicago, Dr. Stacey was appointed as the President and Chief Executive Officer of the Poudre Valley Health System in Fort Collins in 1996. During his stay in Fort Collins Dr. Stacey has become nationally recognized for his innovative approach to working with physicians to better provide healthcare in a seamless environment. In 2004 the Poudre Valley Health System became the first organization in any industry to receive the prestigious Peak Award from the Colorado Performance Excellence Institute for their work on the quality process. In 2005 and 2006 Poudre Valley Health System was a finalist for the prestigious Malcolm Baldrige National Quality Award.

Dr. Stacey currently serves at the Regent for Colorado for the American College of Healthcare Executives, and has been asked to serve as the only healthcare administration appointment to the American Hospital Association’s Committee on Governance.

Dr. Stacey has a bachelor’s degree in Economics and a master’s degree in Health Administration from Brigham Young University. He has a Ph.D. from the Graduate School of Public Affairs of the University of Colorado at Denver, where he also was named a Milstein Scholar for writing the best dissertation of the year in 2000.

Dr. Stacey and his wife Linda are the proud parents of four daughters – Laura, Maria, Jennifer, and Catherine – and one grandson Braden.

Dr. Dan Stinchcomb, Chief Executive Officer
InViragen, Inc.

Dan Stinchcomb is Chief Executive Officer and co-founder of Inviragen, a biotechnology company focused on developing life-saving vaccines for emerging infectious diseases worldwide. Since initiating operations for Inviragen in January, 2005, Dan successfully raised over $5.2 million in grant and seed investor funding, established Inviragen’s product and business strategies, opened its office and laboratory facilities in Fort Collins and established key collaborations with international vaccine manufacturers, non-profit vaccine initiatives, government research organizations and university researchers. Inviragen won the CBSA Venture Showcase competition in 2005 and the Rising Star Award in 2007. Dr. Stinchcomb brings over twenty years of biotechnology management and scientific experience to Inviragen. Formerly, Dan was Executive Vice President of Research and Development at Heska Corporation and held scientific management positions at Ribozyme Pharmaceuticals (now Sirna, acquired by Merck) and Synergen (acquired by Amgen). Prior to joining Synergen, Dan was an Associate Professor in Cellular and Developmental Biology at Harvard University. Dan is an inventor on over 20 issued US patents and has authored more than 30 scientific articles. He received his PhD degree in Biochemistry from Stanford University and a BA degree from Harvard. Dr. Stinchcomb is also an Adjunct Professor of Molecular Biology and Biochemistry at Colorado State University.

Greg Tucker, Vice President, Strategic Management and Operations
OSI Pharmaceuticals

Greg Tucker has 18 years experience in the pharmaceutical industry. He has worked in a variety of commercial capacities in larger pharma (Roche), mid-size pharma (Gilead), small start-up firms (Synergen, NeXstar) as well as the medical device industry (COBE BCT). His experience includes leadership assignments in business development, strategic planning, new product planning, marketing, sales, managed care, commercial operations, project management and strategic brand management.

While at OSI, Mr. Tucker has held a variety of positions in the Oncology Commercial Group. He served as Project Head for the Team that licensed the oncology rights to Novantrone from Serono. As Senior Director, Marketing and Sales, he was responsible for building and leading the Marketing, Sales,Training and Operations groups at OSI. Subsequently, he was promoted to Vice President, US Commercial Operations expanding his executive role in the Oncology Business Unit at OSI. Currently, he holds the position of Vice President, Strategic Management and Operations where he leads company activities for strategic brand management, project management, portfolio management and business decision and analysis.

Mr. Tucker holds a BS in Pharmacy from the University of Arkansas and a MS in Health Administration (specialty in Pharmaceutical Marketing) from the University of Mississippi.

Jack Wheeler

M. Roy Wilson, M.D., M.S., Chancellor
University of Colorado Denver

Dr. M. Roy Wilson began serving as chancellor of the University of Colorado Denver (UC Denver) in July, 2006. UC Denver consists of a general academic campus with 7 schools and colleges and a health sciences campus with schools and colleges of Medicine, Nursing, Pharmacy, Dental Medicine, and Public Health, as well as the Graduate School of Biomedical Sciences.

In addition to the board of the University of Colorado Hospital, for which he is the chairman, Dr. Wilson serves on the governing boards of the Denver Children’s Hospital, Auraria Higher Education Center, Fitzsimons Redevelopment Authority, Institute of International Education, and the Colorado Bioscience Association. He currently serves on the Advisory Council of the National Center for Research Resources of NIH. He is an elected member of the Institutes of Medicine of the National Academy of Sciences, the American Opthalmological Society, and the Glaucoma Research Society.

Dr. Wilson received his medical degree from Harvard Medical School and his Master of Science in epidemiology at the UCLA School of Public Health. Dr. Wilson has been selected in “Best Doctors in America” for multiple consecutive years since 1996 and was selected again for 2007-2008. Among his many awards is the Association of American Medical College’s Herbert W. Nickens Award which he received in November, 2007.

Ed Wood, CEO
ArcScan, Inc.

Ed Wood was the founding CEO of COBE BCT, Inc, now Gambro BCT, Inc. Ed is now the CEO of ArcScan, an emerging device company and is serving on the Board of Directors of four medical device and biotech companies, both public and private. He volunteers for CBSA as well as homeowner associations in Morrison and in Keystone. He and his wife Janice are proud of the two sons they have raised in Colorado.